Chelsea Therapeutics (NASDAQ: CHTP) Acquired by Lundbeck (LUN.CO)

Brian Hicks

Written By Brian Hicks

Posted May 8, 2014

Danish pharmaceutical company H. Lundbeck A/S announced on Thursday that it is acquiring North Carolina-based Chelsea Therapeutics (NASDAQ: CHTP) for approximately $658 million.

Chelsea makes a blood pressure drug called Northera (droxidopa) that recently received FDA approval for launch in 2014. The drug is useful in the treatment of neurological conditions such as Parkinson’s Disease, and could potentially be useful in the treatment of such conditions as fibromyalgia and intradialytic hypotension.

Lundbeck described this drug as “an orphan neurology opportunity with strong commercial and strategic fit with Lundbeck’s existing U.S. neurology franchise.”

Chelsea stockholders will receive $6.44 per share in cash and CVRs that could add $1.50 depending upon how Northera performs on the market between 2015 and 2017. Shares closed at $5.00 yesterday.


Investing in Hydropower

Are you changing your portfolio according to the United States’ changing energy mix? You should be. The brightest outlook is in solar power, and domestic oil and gas. Hydropower is being pushed by the government in a new report, but it is not likely to broaden its use any time soon.

Angel Publishing Investor Club Discord - Chat Now

Brian Hicks Premium

Introductory

3 Stocks for Lithium's 4,000% Rise

The single most important geological discovery of our generation has just taken place. And it could be responsible for a MASSIVE rise in lithium prices. The best part? A Tiny mining firm is at the forefront of mining the world's largest lithium deposit... And it's not overseas in some politically unstable nation... Every single ounce of this record-breaking deposit is right here in America. Our latest report highlights this story and offers you access to our FREE Report that details 3 lithium stocks to buy now.

Sign up to receive your free report. After signing up, you'll begin receiving the Energy and Capital e-letter daily.